Royalty Report: Drugs, Delivery, Personal Care Products – Collection: 26964


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Delivery
  • Personal Care Products
  • Cancer
  • Content
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26964

License Grant
The Company obtained a non-exclusive license over the HIT Technology to exclusively exploit its anti-cancer HyACT(TM) project worldwide.
License Property
Hyaluronan Induced Targeting (HIT) is topical drug delivery technologies, based on hyaluronan (HA), a natural polymer, which are primarily designed to maintain efficacy and localize delivery of drugs to the skin for the treatment of a variety of skin disorders.
Field of Use
The rights granted apply to skin disorders.

IPSCIO Record ID: 27344

License Grant
In 1987, the Company has licensed from the University on a worldwide exclusive basis three United States and six foreign patents providing coverage in 17 counties outside of the U.S. for the technology underlying the TopiCare Delivery Compounds for the life of the patents.
License Property
TopiCare Delivery Compounds consist of a broad portfolio of liquid polymers that can be designed to deposit an active ingredient and optimize penetration at targeted levels of skin tissue where particular disease conditions can be effectively treated.  For example, formulations currently in development containing TopiCare Delivery Compounds deliver an antifungal agent to the upper epidermis, a skin layer where fungus predominates.
Field of Use
The Company’s TopiCare Delivery Compounds represent a patented skin-loading technology designed to target delivery to layers in the skin or other epithelial tissue.

IPSCIO Record ID: 1724

License Grant
The Company entered into a second exclusive, worldwide, royalty bearing license agreement with the University for two patents, the rights to which are jointly held by the Licensor and Cellegy, for Drug Delivery By Skin Barrier Disruption.
License Property
This technology selectively modulates the skin’s barrier, with the goals of opening the skin barrier wider and keeping it open for a longer period of time (which may allow for the transdermal and topical delivery of larger and/or water soluble therapeutic, nutritional and cosmetic molecules), and reducing the potential for inducing skin inflammation, which sometimes accompanies use of certain traditional drug delivery technologies.
Field of Use
The rights granted apply to skin's barrier.

IPSCIO Record ID: 2271

License Grant
In 1989, the Company discontinued its operations and assigned its the rights to Skin Fresh Methodology.
License Property
Skin Fresh Methodology  for the treatment of acne, eczema, psoriasis, contact dermatitis, seborrhea, and other less serious skin disorders.

The Skin Fresh treatment program avoids the use of prescription drugs taken internally, and includes a regimen and the topical application of FDA approved antibiotics.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.